Wed, Aug 27, 2014, 9:28 AM EDT - U.S. Markets open in 2 mins.

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • NhanDuyVo NhanDuyVo Jul 10, 2012 9:47 AM Flag

    Ricardo - CLDX

    Good Morning Ricardo:

    You mentioned in the other post that you took a position in CLDX based on the latest report on phase 2b clinical trial of CDX-011 for treatment of breast cancer.

    I read the report and your post as well. What do you think about the chance of success the the trial in the Triple Negative and High GPNMB Expression?

    Please express your sentiment on CDX-011 in this indication.

    Thank you for your expertise in this area.

    Best regards,

    Nhan

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Nhan,

      My investment in CLDX is relatively small compared to my long position in SGEN. I consider it to be a speculative holding.

      I believe that I initially took a position in CLDX a while back when it was about $2.50. I have subsequently added a bit more periodically in the 4 to 5 range.

      My initial investment thesis was based on enthusiasm for the SGEN ADC technology. I was trying to find a company with a promising developmental stage product using that technology.....especially one that was well leveraged to the upside in that respect. CDLX, at the time, fit the bill as it had a relatively low market cap and CDX-011 in the works.

      I would rate the chances of CDX-011 as being "fairly decent" with regards to eventual approval in the indication of Triple negative breast disease with high GPNMB expression. Of course, that depends quite a bit on the patient selection regarding what constitutes "high expression". My gut feeling ( just my personal very speculative impression only ) is that within a properly selected cohort population the drug will show good clinical activity and may well merit consideration for eventual regulatory approval in this setting. If pressed to give odds of success I would venture 50-50, but there critically has to be appropriate patient selection trial criteria.

      50-50 is, indeed, good enough for Ricardo to make a speculative wager on an early stage developmental company, provided that the entry is at a point of relatively lower market cap and high upside leverage potential.

      As a warning: This is only my personal viewpoint. Investors should make their own decisions to buy sell or hold.

      Ricardo

      -------

      Bias: Ricardo is burying himself in this SGEN ADC technology. He could be on food stamps some time in the future due to his "irrational exuberance" The man needs help.

 
SGEN
44.09Aug 26 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.